Table 4.
Survival of patients ≥ 75 years treated with or without neoadjuvant chemotherapy, and by anthracycline-based triplet therapy and FLOT regimen
| Neoadjuvant chemotherapy age ≥ 75 (N = 275) | No neoadjuvant chemotherapy age ≥ 75 (N = 471) | P-value | |
|---|---|---|---|
| Overall survival (months), median (95% CI) | 34.9 (29.2–40.7) | 32.3 (26.3–38.3) | 0.506 |
| 3-year overall survival % | 49 | 47 | |
| 5-year overall survival % | 36 | 36 | |
| Unjadusted hazard ratio (95% CI) | 0.93 (0.76–1.14) | 1 | 0.506 |
| Adjusted hazard ratio (95% CI)* | 0.87 (0.67–1.12) | 1 | 0.263 |
| EOX/ECC/EOF/ECF (N = 119) | FLOT (N = 77) | P-value | |
|---|---|---|---|
| Overall survival (months), median (95% CI) | 34.1 (27.1–41.2) | – | 0.164 |
| 3-year overall survival % | 46 | 56 | |
| 5-year overall survival % | 35 | – |
EOX epirubicine, oxaliplatin, capecitabine, ECC epirubicine, cisplatin, capecitabine, EOF epirubicine, oxaliplatin, 5-fluorouracil, ECF epirubicine, cisplatin, 5-fluoruracil, FOLFOX 5-fluorouracil, oxaliplatin, CAPOX capecitabine, oxaliplatin, FLOT 5-fluorouracil, leucovorin, oxaliplatin, docetaxel, DOC docetaxel, oxaliplatin, capecitabine
*Adjusted for age, sex, WHO performance status, number of comorbidities, tumor location, cT-stage, cN-stage, and tumor differentiation